fbpx Skip to main content

Member's Profile

Phoenix Molecular Designs

3210 Merryfield RowRoom 5800E
San Diego,   CA
United States
Membership Info
Membership Type: Industry
Membership Since: 2017
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About Phoenix Molecular Designs
Biotech Company
Phoenix Molecular Designs (PhoenixMD) has patented the first orally available small molecules targeting RSK, an entirely new drug target for cancer. Our immediate focus is to develop the first targeted therapy for the effective treatment of Triple Negative Breast Cancer (TNBC), the most aggressive form of breast cancer with poor survival rates. PMD-026, our clinical lead, blocks the growth of TNBC in mice and is active against multiple PDx models. Excellent safety is also a hallmark of this impressive new cancer therapy. Clinical trials are scheduled to begin in 2019 on the backing of a team with deep experience in developing marketed cancer drugs. Beyond breast cancer, PMD-026 is active against several other types of cancer. PhoenixMD operates in Vancouver BC, and San Diego, California.
Related News
No related news posted by this Member